A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues

Drug Metabolism and Disposition

Volumn 38, Issue 6, 2010, Pages 988-994

  Hart, Steven N ^a   Li, Ye ^a   Nakamoto, Kaori ^a   Subileau, Eva Anne ^b   Steen, David ^b   Zhong, Xiao Bo ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b BIOPREDIC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARCINOMA CELL; CELL STRAIN HEPG2; FEMALE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HEPARG CELL; HUMAN; HUMAN CELL; HUMAN GENOME; HUMAN TISSUE; LIVER; LIVER CELL; PRIORITY JOURNAL; TRANSCRIPTOMICS;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELLS, CULTURED; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENOME; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIVER; MALE; XENOBIOTICS;

EID: 77952300660     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.031831     Document Type: Article

References (23)

1. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, and Guillouzo A (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75-83. (Pubitemid 43042648)
2. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, and Lempicki RA (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4:P3.
3. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, and Guguen-Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99:15655-15660.
4. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, and Guguen-Guillouzo C (2007) The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 168:66-73. (Pubitemid 46659919)
5. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
6. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, and Speed TP (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15.
7. Kanebratt KP and Andersson TB (2008a) Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:1444-1452.
8. Kanebratt KP and Andersson TB (2008b) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36:137-145.
9. Kato M, Chiba K, Horikawa M, and Sugiyama Y (2005) The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 20:236-243.
10. Lambert CB, Spire C, Claude N, and Guillouzo A (2009a) Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol 234:345-360.
11. Lambert CB, Spire C, Renaud MP, Claude N, and Guillouzo A (2009b) Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro 23:466-475.
12. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, and Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215-2220.
13. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, and Fardel O (2006) Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28:109-117.
14. LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, and Parkinson A (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177-188.
15. LeCluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343-368.
16. Luo G, Guenthner T, Gan LS, and Humphreys WG (2004) CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 5:483-505. (Pubitemid 39534494)
17. Ogino M, Nagata K, and Yamazoe Y (2002) Selective suppressions of human CYP3A forms, CYP3A5 and CYP3A7, by troglitazone in HepG2 cells. Drug Metab Pharmacokinet 17:42-46.
18. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, et al. (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56-67.
19. Richert L, Liguori MJ, Abadie C, Heyd B, Mantion G, Halkic N, and Waring JF (2006) Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab Dispos 34:870-879.
20. Rodríguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, and Gómez-Lechón MJ (2002) Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32:505-520.
21. Sassa S, Sugita O, Galbraith RA, and Kappas A (1987) Drug metabolism by the human hepatoma cell, Hep G2. Biochem Biophys Res Commun 143:52-57. (Pubitemid 17030463)
22. Wettenhall JM, Simpson KM, Satterley K, and Smyth GK (2006) affylmGUI: a graphical user interface for linear modeling of single channel microarray data. Bioinformatics 22:897-899.
23. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, and Spencer F (2004) A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 99:909. (Pubitemid 39665934)